Breast Cancer

Most Women Have an Inaccurate Perception of Their Breast Cancer Risk

Breast Cancer Symposium
September 4, 2013

A large-scale survey of Long Island women who were having mammography to screen for breast cancer shows that the majority (more than 90%) either under- or overestimated their risk of developing this disease during their lifetime. Additionally, four out of every 10 women surveyed (40%) said they had never discussed their personal breast cancer risk with a doctor.

Having an MRI Around the Time of Surgery Does Not Reduce Recurrence Rates in Women with DCIS

Breast Cancer Symposium
September 4, 2013

A new study has found that using magnetic resonance imaging (MRI), in addition to mammography, before or immediately after a lumpectomy (surgical removal of the tumor and a small, cancer-free margin of tissue around the tumor) was not linked to a decrease in how often women with ductal carcinoma in situ (DCIS) of the breast experienced a local recurrence (cancer that comes back in the same area of the breast after treatment) or contralateral breast cancer (a new tumor that develops in the other breast).

For Early-Stage Breast Cancer, Lymph Node Radiation Therapy Works as Well as Surgery with a Lower Risk of Lymphedema

ASCO Annual Meeting
June 3, 2013

Results from a recent study show that directing radiation therapy to the underarm lymph nodes works as well as removing the lymph nodes with surgery and is less likely to cause lymphedema for women with early-stage breast cancer. Lymphedema is the abnormal buildup of fluid (lymph) in the arm, causing swelling that can be painful and limit a person’s movement. It is a common side effect from both surgery and radiation therapy to the underarm lymph nodes. 

Two Commonly Used Paclitaxel Chemotherapy Schedules are Equally Effective for Early-Stage Breast Cancer, but One Has Fewer Side Effects

ASCO Annual Meeting
June 3, 2013

Women with higher-risk, early-stage breast cancer who received weekly chemotherapy with paclitaxel (Taxol) after surgery as part of a clinical trial lived for the same amount of time without the cancer returning as those who received higher doses of the same drug every two weeks (known as dose-dense therapy). However, the researchers found that the women who received chemotherapy every week experienced fewer and less serious treatment-related side effects.

Pages

Subscribe to RSS - Breast Cancer